1. A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations.
- Author
-
Desvignes C, Ternant D, Lecomte T, Lièvre A, Ohresser M, Chautard R, Raoul W, and Paintaud G
- Subjects
- Antibodies, Monoclonal, Humanized therapeutic use, Colorectal Neoplasms drug therapy, Humans, Ramucirumab, Antibodies, Monoclonal, Humanized blood, Colorectal Neoplasms blood, Enzyme-Linked Immunosorbent Assay
- Abstract
Aim: Ramucirumab, an anti-VEGFR2 monoclonal antibody, has been approved for the treatment of metastatic gastric and colorectal cancer. An assay measuring ramucirumab serum concentrations was needed to investigate its pharmacokinetics and concentration-response relationship. Results: An ELISA was developed and validated according to the international guidelines for ligand-binding assays. Ramucirumab calibration standards ranged from 0.125 to 40 mg/l. Low, middle and high quality controls were spiked at 0.2, 4 and 8 mg/l, respectively. The limits of quantification were established to be 0.125 and 10 mg/l for LLOQ and ULOQ, respectively. No cross-reactivity with anti-VEGF or anti-EGFR was detected. Conclusion: This in-house-developed ELISA is sensitive, accurate, reproducible and suitable for pharmacokinetic studies of ramucirumab.
- Published
- 2021
- Full Text
- View/download PDF